Active substance
Menotropins
- US FDA 5
- Health Canada 1
- US price lines 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| MENOPUR | 75 IU/VIAL;75 IU/VIAL | injectable · subcutaneous | FERRING | Prescription | 29 Oct 2004 |
| PERGONAL | 75 IU/AMP;75 IU/AMP; 150 IU/AMP;150 IU/AMP | injectable · injection | SERONO | Discontinued | 22 Aug 1975 |
| HUMEGON | 75 IU/VIAL;75 IU/VIAL; 150 IU/VIAL;150 IU/VIAL | injectable · injection | ORGANON USA INC | Discontinued | 1 Sep 1994 |
| REPRONEX | 75 IU/VIAL;75 IU/VIAL | injectable · intramuscular, subcutaneous | FERRING | Discontinued | 27 Aug 1999 |
| REPRONEX | 150 IU/VIAL;150 IU/VIAL | injectable · injection | FERRING | Discontinued | 27 Aug 1999 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| MENOPUR | 02283093 | 75 UNIT / VIAL | POWDER FOR SOLUTION · SUBCUTANEOUS | FERRING INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | MENOPUR 75 UNIT VIAL | $252.1192 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.